Healthcare
Live Price
Offline$0.015
+0.00% today
Window Change
-99.80%
Window
Jun 23, 2025 → May 15, 2026
Coverage: 227 bars · Jun 23, 2025 → May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaxxinity, Inc. (VAXX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 99.8% across the available one-year price window (Jun 23, 2025 → May 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.9%, free cash flow -0.4% with operating margin 0.0% and ROIC -203.7%. Stock Foundry combines VAXX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VAXX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VAXX Max Drawdown
-100.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VAXX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$14.2M
+64.4% YoY
Free Cash Flow
-$12.3M
+65.3% YoY
Revenue Growth
+0.0%
EPS Growth
+99.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 66K | 557K | 0 |
| Gross Profit | -2M | -2M | -2M | 505K | -107K |
| Operating Income | -58M | -76M | -125M | -32M | -14M |
| EBITDA | -54M | -73M | -135M | -38M | -14M |
| Net Income | -57K | -75M | -137M | -40M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 33M | 145M | 31M | 476K |
| Total Assets | 44M | 106M | 167M | 50M | 2M |
| Total Liabilities | 31M | 44M | 38M | 138M | 50M |
| Shareholder Equity | 13M | 62M | 129M | -87M | -49M |
| Total Debt | 15M | 15M | 11M | 38M | 14M |
| Net Debt | 10M | -19M | -134M | 7M | 14M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+63.8% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
12M
+65.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.2%
Debt / Equity
1.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.